ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0451

Macrophages and Interferon Upregulation in Placentas from Patients with Systemic Lupus Erythematosus, Primary Sjögren’s Disease and Antiphospholipid Syndrome

Juan J. Fierro1, Mirthe Schoots1, Silvia Liefers1, Berber Doornbos-van der Meer2, Gilles Diercks1, Hendrika Bootsma3, Jelmer R. Prins1, Johanna Westra1 and Karina de Leeuw4, 1University Medical Center Groningen, University of Groningen, Groningen, Groningen, Netherlands, 2University Medical Center Groningen, University of Groningen, Groningen, Netherlands, 3Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Groningen, Netherlands, 4University Medical Center Groningen, Groningen, Groningen, Netherlands

Meeting: ACR Convergence 2024

Keywords: antiphospholipid syndrome, pregnancy, Sjögren's syndrome, Systemic lupus erythematosus (SLE), Women's health

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Reproductive Issues in Rheumatic Disorders Poster

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: SLE, primary Sjögren’s disease (pSjD) and APS are systemic rheumatic diseases (SRD) that mainly affect women of childbearing age and have been associated with adverse pregnancy outcomes (APO). This study aims to identify immunological imbalances in placentas from patients with SLE, pSjD or APS, focusing on IFN and immune cell subsets compared to placentas of healthy pregnancies and of APO of women without these SRD.

Methods: Placenta biopsies from healthy controls (HC), SLE, pSjD, APS and control patients with fetal growth restriction (FGR), preterm birth (PTB), or FGR and preeclampsia (FGR/PE) were recovered from the pathology biobank at our university hospital. Clinical characteristics and APO were retrieved from medical records. APO were defined as the presence of PTB, FGR, PE or thromboembolic events during pregnancy or postpartum. Immunohistochemistry was performed for Myxovirus resistance protein 1 (MxA), CD3, CD20, CD56, CD68, and CD123. The proportion of positive cells was established using an automated detection classifier, while MxA expression was assessed semi/quantitatively discriminating between maternal (decidua) and fetal (villi) tissue. Finally, placental lesion classification was performed according to the Amsterdam Workshop Group recommendations.

Results: Our study included placentas from 11 SLE, 4 pSjD, 8 APS, 8 FGR, 8 FGR/PE patients and 11 HC. Demographic and disease characteristics before pregnancy are summarized in Table 1. Patients with SRD had a high rate of APO (70%). The most common APO in SLE patients was PTB (54.5%), followed by FGR (27.3%), while APS patients had high rates of PTB (75%) and PE (63%). SRD patients had higher macrophage (CD68+) counts in decidua and villi than HC as depicted in Figure 1. In decidua, this difference was found in the placentas of SLE and APS patients, while in villi, pSjD patients also had higher macrophage counts. Concerning patients without SRD, in decidua, only PTB showed an increase macrophage count compared to HC. In villi, this difference was significant for PTB, FGR and FGR/PE patients. No differences were observed in T (CD3+), B (CD20+) and NK (CD56+) cells between patients with SRD and HC in decidua and villi, and no plasmacytoid dendritic cells (CD123+) were identified. Patients with SRD had higher MxA values than HC in villi but not decidua and this difference was explained by SLE and pSjD patients, while APS patients did not show significant differences with HC. PTB, FGR and FGR/PE groups were associated with a higher MxA expression in villi compared to HC, which was not the case for decidua tissue. Finally, placental lesions were frequently found in SRD patients, while SLE patients had a high prevalence of chorioamnionitis (CA) (55%), APS patients had higher rates of maternal vascular malperfusion (75%) and villitis of unknown etiology (38%).

Conclusion: SLE, pSjD and APS patients have an increased macrophage count and interferon upregulation in the placenta compared to HC. This upregulation seems to occur in the chorionic villi rather than the decidua. Therefore, a pro-inflammatory environment led by innate immune components seems to be the main cause of placental dysfunction and APO presentation.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: J. Fierro: None; M. Schoots: None; S. Liefers: None; B. Doornbos-van der Meer: None; G. Diercks: None; H. Bootsma: Argenx, 2, AstraZeneca, 2, 12, Funding, Bristol Myers Squibb, 2, 12, Funding, Galapagos, 2, Novartis, 2, 12, Funding, Roche, 2, 12, Funding, Sanofi, 2, UCB, 2; J. Prins: None; J. Westra: None; K. de Leeuw: None.

To cite this abstract in AMA style:

Fierro J, Schoots M, Liefers S, Doornbos-van der Meer B, Diercks G, Bootsma H, Prins J, Westra J, de Leeuw K. Macrophages and Interferon Upregulation in Placentas from Patients with Systemic Lupus Erythematosus, Primary Sjögren’s Disease and Antiphospholipid Syndrome [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/macrophages-and-interferon-upregulation-in-placentas-from-patients-with-systemic-lupus-erythematosus-primary-sjogrens-disease-and-antiphospholipid-syndrome/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/macrophages-and-interferon-upregulation-in-placentas-from-patients-with-systemic-lupus-erythematosus-primary-sjogrens-disease-and-antiphospholipid-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology